FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:922-924 August 27, 2009 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

By the time the sequencing of the human genome was completed 6 years ago, expectations were huge that this knowledge would soon have an impact on our ability to treat disease, nowhere more so than in oncology. The genome sequence itself amounted to no more than a parts list, with minimal clues to function. Fortunately, however, at about the same time a powerful technology for rapidly probing the biologic roles of genes became available in the form of RNA interference. The coming together of these two breakthroughs, which make up part of what is often referred to as "functional genomics," . . . [Full Text of this Article]

Source Information

From the Cancer Research UK London Research Institute, London.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.